Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 5
2021 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam.
Hujer AM, Marshall SH, Mack AR, Hujer KM, Bakthavatchalam YD, Umarkar K, Palwe SR, Takalkar S, Joshi PR, Shrivastava R, Periasamy H, Bhagwat SS, Patel MV, Veeraraghavan B, Bonomo RA. Hujer AM, et al. Among authors: palwe sr. mBio. 2023 Oct 27;14(6):e0111823. doi: 10.1128/mbio.01118-23. Online ahead of print. mBio. 2023. PMID: 37889005 Free PMC article.
In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Bhagwat SS, Legakis NJ, Skalidis T, Loannidis A, Goumenopoulos C, Joshi PR, Shrivastava R, Palwe SR, Periasamy H, Patel MV, Chatzipanagiotou S; Hellenic Cefepime/Zidebactam Study Group. Bhagwat SS, et al. Among authors: palwe sr. Diagn Microbiol Infect Dis. 2021 Jul;100(3):115327. doi: 10.1016/j.diagmicrobio.2021.115327. Epub 2021 Jan 30. Diagn Microbiol Infect Dis. 2021. PMID: 33744624
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy.
Barceló I, Cabot G, Palwe S, Joshi P, Takalkar S, Periasamy H, Cortés-Lara S, Zamorano L, Sánchez-Diener I, Moya B, Bhagwat S, Patel M, Oliver A. Barceló I, et al. Among authors: palwe s. J Antimicrob Chemother. 2021 Sep 15;76(10):2546-2557. doi: 10.1093/jac/dkab213. J Antimicrob Chemother. 2021. PMID: 34219168
In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations.
Palwe S, Bakthavatchalam YD, Khobragadea K, Kharat AS, Walia K, Veeraraghavan B. Palwe S, et al. Antibiotics (Basel). 2021 Oct 29;10(11):1318. doi: 10.3390/antibiotics10111318. Antibiotics (Basel). 2021. PMID: 34827256 Free PMC article.
Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
Bhagwat SS, Hariharan P, Joshi PR, Palwe SR, Shrivastava R, Patel MV, Devanga Ragupathi NK, Bakthavatchalam YD, Ramesh MS, Soman R, Veeraraghavan B. Bhagwat SS, et al. Among authors: palwe sr. J Antimicrob Chemother. 2020 Dec 1;75(12):3563-3567. doi: 10.1093/jac/dkaa353. J Antimicrob Chemother. 2020. PMID: 32772098
In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.
Moya B, Barcelo IM, Cabot G, Torrens G, Palwe S, Joshi P, Umarkar K, Takalkar S, Periasamy H, Bhagwat S, Patel M, Bou G, Oliver A. Moya B, et al. Among authors: palwe s. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e00128-19. doi: 10.1128/AAC.00128-19. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30782985 Free PMC article.